Copy Link Print Information

Sunitinib Malate

(Synonyms: SU 11248 Malate)
106 Cited Publications
Kundenbewertung

Based on 106 publication(s) in Google Scholar

Sunitinib (SU 11248) Malat is a multi-targeted receptor tyrosine kinase inhibitor with IC50s of 80 nM and 2 nM for VEGFR2 and PDGFRβ, respectively. Sunitinib Malat, an ATP-competitive inhibitor, effectively inhibits autophosphorylation of Ire1α by inhibiting autophosphorylation and consequent RNase activation.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

  • Reinheit: 99.74%
  • CAS. Nr.: 341031-54-7
  • Formel: C26H33FN4O7
  • Molecular Weight:532.56
  • Speicherung:

    4°C, sealed storage, away from moisture

    * In solvent : -80°C, 2 years; -20°C, 1 year (sealed storage, away from moisture)

  • Sunitinib Malate Chemical Structure
    Sunitinib Malate Chemical Structure
  • Experimental Validation Results for Sunitinib Malate
  • Experimental Validation Results for Sunitinib Malate
  • Experimental Validation Results for Sunitinib Malate
  • Experimental Validation Results for Sunitinib Malate
  • Experimental Validation Results for Sunitinib Malate
  • Experimental Validation Results for Sunitinib Malate
  • Experimental Validation Results for Sunitinib Malate
  • Experimental Validation Results for Sunitinib Malate
  • Experimental Validation Results for Sunitinib Malate
  • Experimental Validation Results for Sunitinib Malate
  • Experimental Validation Results for Sunitinib Malate
  • Experimental Validation Results for Sunitinib Malate
CAS. Nr.: 341031-54-7
Größe
Preis
Verfügbarkeit
Menge
Amount: USD 0.00
Please select quantity
or
or

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

To place orders, for customer services and technical support, please contact: MedChemExpress USA

Tel: 609-228-6898 E-mail: [email protected] [email protected]

Data Download
Other Forms of Sunitinib Malate:

To place orders, for customer services and technical support, please contact:

609-228-6898
[email protected] [email protected]
Finden Sie Ihren Händler vor Ort Your local distributor: Hycultec GmbHHycultec
  • Biologische Aktivität
  • Chemical Information
  • Lösungsmittel & Löslichkeit
  • Protokoll
  • Reinheit & Dokumentation
  • Verweise
  • Help & FAQs
You May Still Need
Top Publications Citing

Use of MCE Products

Publications Citing Use of MedChemExpress (MCE) Sunitinib Malate

More
Customer Validation & Images
WBRT-PCRIHCCell Proliferation/Viability AssayIF
  • Cell Proliferation/Viability Assay
  • IF
  • WB
  • WB
  • WB
  • IHC
  • WB
  • WB
  • WB
  • WB
  • WB
  • RT-PCR

Alle PDGFR Isoform-spezifische Produkte anzeigen

More

Alle VEGFR Isoform-spezifische Produkte anzeigen

More
Keywords
100 mg

Angebot einholen Auf Lager

Please select quantity
Amount: USD 0.00
Sign in to MedChemExpress Einloggen
Registrieren
Sign in to MedChemExpress
Neuen Account Registrieren

At least 6 characters

Personalize your experience, you are currently not signed in. For a better experience, please create an online profile, you can:

Obtain points redemption prizes
Check out faster
Add multiple shipping locations
View orders
Assay Types
  • Sunitinib Malate Chemical Structure
    Sunitinib Malate Chemical Structure
    1/16
  • 1/16

    Sunitinib Malate purchased from MedChemExpress. Usage Cited in: J Pharm Anal. 2023 May;13(5):514-522. [Abstract]

    Customer Validation
     Sunitinib (0-100 μM; 72 h) induces significant cell death in T98G cells.

  • 1/16

    Sunitinib Malate purchased from MedChemExpress. Usage Cited in: J Pharm Anal. 2023 May;13(5):514-522. [Abstract]

    Customer Validation
     Sunitinib (3 μM; 24 h) increases the expression of γ-H2Ax and Temozolomide (TMZ; 10 μM; 24 h) increases the induction of Sunitinib, in T98G cells.

  • 1/16

    Sunitinib Malate purchased from MedChemExpress. Usage Cited in: J Pharm Anal. 2023 May;13(5):514-522. [Abstract]

    Customer Validation
     Sunitinib (3 μM; 24 h) increases the expression of γ-H2Ax and Temozolomide (TMZ; 10 μM; 24 h) increases the induction of Sunitinib, in T98G cells.

  • 1/16

    Sunitinib Malate purchased from MedChemExpress. Usage Cited in: Theranostics. 2018 Jul 30;8(15):4262-4278. [Abstract]

    Customer Validation
     BV2 cells are pretreated with 0.1% DMSO (Ctrl), JuA (25 µM) or JuA (25 µM) with the indicated antagonist of RTKs (Dovitinib at 1 µM, Gefinitib at 2.5 µM, Sunitinib at 2.5 µM and LDC1267 at 1 µM) for 30 min, followed by administration of Aβ42 (5 μM) for 12 h.

  • 1/16

    Sunitinib Malate purchased from MedChemExpress. Usage Cited in: EBioMedicine. 2018 Nov:37:344-355. [Abstract]

    Customer Validation
     Sutent (Sunitinib Malate) treatment decreases lipid accumulation in adipose and liver tissues and increases UCP1 expression in brown adipose tissue. Western blot analysis of UCP1 protein expression level in mouse brown adipose.

  • 1/16

    Sunitinib Malate purchased from MedChemExpress. Usage Cited in: EBioMedicine. 2018 Nov:37:344-355. [Abstract]

    Customer Validation
     Sutent (Sunitinib Malate) treatment decreases lipid accumulation in adipose and liver tissues and increases UCP1 expression in brown adipose tissue. Representative images of immunohistochemistry stainining of UCP1 in BAT.

  • 1/16

    Sunitinib Malate purchased from MedChemExpress. Usage Cited in: Oncotarget. 2017 Nov 15;8(67):111110-111118. [Abstract]

    Customer Validation
     In cell EC50 determination of CHMFL-KIT-031 with parental Colo320DM (KIT wt) and KIT V559D overexpressed Colo320DM cells.

  • 1/16

    Sunitinib Malate purchased from MedChemExpress. Usage Cited in: Oncotarget. 2017 Jul 27;8(56):95116-95134. [Abstract]

    Customer Validation
     Abemaciclib causes increased PARP cleavage in RCC. In 786-O cells Abemaciclib exposure results in increased PARP cleavage. This effect is more rapid and pronounced when Abemaciclib is combined with Sunitinib.

  • 1/16

    Sunitinib Malate purchased from MedChemExpress. Usage Cited in: Oncotarget. 2017 Jul 27;8(56):95116-95134. [Abstract]

    Customer Validation
     Abemaciclib causes increased PARP cleavage in RCC. In Caki-1 cells Abemaciclib exposure results in increased PARP cleavage. This effect is more rapid and pronounced when Abemaciclib is combined with Sunitinib.

  • 1/16

    Sunitinib Malate purchased from MedChemExpress. Usage Cited in: J Med Chem. 2016 Sep 22;59(18):8456-72. [Abstract]

    Customer Validation
     Effect of compounds 1 (Imatinib), 2 (Sunitinib), and 35 on cKIT mediated signaling pathways in GIST-T1 and GIST-5R cancer cell lines.

  • 1/16

    Sunitinib Malate purchased from MedChemExpress. Usage Cited in: Int J Clin Exp Pathol. 2015 Apr 1;8(4):3871-81. [Abstract]

    Customer Validation
     The relationship between SOX9 and Raf/MEK/ERK signaling pathway. Co-treatment of si-SOX9-1 and Sorafenib (10uM, 15uM)/Sunitinib (2 uM, 3 uM) significantly decreases expression of MEK1 and its phosphorylated protein (p-MEK1/2, p-ERK1/2) as assayed by Western blot (with GAPDH as internal control).

  • 1/16

    Sunitinib Malate purchased from MedChemExpress. Usage Cited in: Int J Clin Exp Pathol. 2015 Apr 1;8(4):3871-81. [Abstract]

    Customer Validation
     The relationship between SOX9 and Raf/MEK/ERK signaling pathway. Co-treatment of si-SOX9-1 and Sorafenib (10uM, 15uM)/Sunitinib (2 uM, 3 uM) significantly decreases expression of MEK1 and its phosphorylated protein (p-MEK1/2, p-ERK1/2) as assayed by RT-PCR (with β-actin as internal control).

  • Sunitinib Malate